{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:21:50Z","timestamp":1793733710415,"version":"4.6.1"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,27]],"date-time":"2024-10-27T00:00:00Z","timestamp":1729987200000},"content-version":"am","delay-in-days":331,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AG062617"],"award-info":[{"award-number":["R01 AG062617"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 NS087070"],"award-info":[{"award-number":["R01 NS087070"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.ejmech.2023.115876","type":"journal-article","created":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T12:12:02Z","timestamp":1697458322000},"page":"115876","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Lipidation and PEGylation strategies to prolong the in vivo half-life of a nanomolar EphA4 receptor antagonist"],"prefix":"10.1016","volume":"262","author":[{"given":"Maricel","family":"Gomez-Soler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika J.","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Rubio de la Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxia","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Lamberto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dillon T.","family":"Flood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waleed","family":"Danho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard C.","family":"Lechtenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan J.","family":"Riedl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip E.","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5076-4848","authenticated-orcid":false,"given":"Elena B.","family":"Pasquale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.115876_bib1","first-page":"3353","article-title":"Characterization of the expression of the Cek8 receptor-type tyrosine kinase during development and in tumor cell lines","volume":"9","author":"Soans","year":"1994","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2023.115876_bib2","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nn994","article-title":"Control of hippocampal dendritic spine morphology through ephrin-A3\/EphA4 signaling","volume":"6","author":"Murai","year":"2003","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ejmech.2023.115876_bib3","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1038\/nn.2394","article-title":"Neuron-glia communication via EphA4\/ephrin-A3 modulates LTP through glial glutamate transport","volume":"12","author":"Filosa","year":"2009","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ejmech.2023.115876_bib4","doi-asserted-by":"crossref","first-page":"7866","DOI":"10.1038\/ncomms8866","article-title":"A draft network of ligand-receptor-mediated multicellular signalling in human","volume":"6","author":"Ramilowski","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115876_bib5","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1038\/s41598-020-58996-3","article-title":"A rare subpopulation of melanoma cells with low expression of metastasis suppressor NME1 is highly metastatic in vivo","volume":"10","author":"Snyder","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2023.115876_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100876","article-title":"A cancer mutation promotes EphA4 oligomerization and signaling by altering the conformation of the SAM domain","author":"Light","year":"2021","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115876_bib7","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.chembiol.2022.01.007","article-title":"Phosphorylation of guanosine monophosphate reductase triggers a GTP-dependent switch from pro- to anti-oncogenic function of EPHA4","volume":"29","author":"Wolff","year":"2022","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.115876_bib8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/nrd4175","article-title":"Therapeutic targeting of EPH receptors and their ligands","volume":"13","author":"Boyd","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.115876_bib9","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1021\/cb500677x","article-title":"Development and structural analysis of a nanomolar cyclic peptide antagonist for the EphA4 receptor","volume":"9","author":"Lamberto","year":"2014","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.115876_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0092309","article-title":"EphA4 activation of c-Abl mediates synaptic loss and LTP blockade caused by amyloid-beta oligomers","volume":"9","author":"Vargas","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2023.115876_bib11","doi-asserted-by":"crossref","first-page":"9959","DOI":"10.1073\/pnas.1405803111","article-title":"Blockade of EphA4 signaling ameliorates hippocampal synaptic dysfunctions in mouse models of Alzheimer's disease","volume":"111","author":"Fu","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2023.115876_bib12","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/ncb3041","article-title":"A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages","volume":"16","author":"Lu","year":"2014","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ejmech.2023.115876_bib13","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1084\/jem.20171413","article-title":"SORLA attenuates EphA4 signaling and amyloid beta-induced neurodegeneration","volume":"214","author":"Huang","year":"2017","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejmech.2023.115876_bib14","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.chembiol.2017.01.006","article-title":"Potent and selective EphA4 agonists for the treatment of ALS","volume":"24","author":"Wu","year":"2017","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.115876_bib15","doi-asserted-by":"crossref","first-page":"7133","DOI":"10.1038\/s41598-017-07325-2","article-title":"Increased EphA4-ephexin1 signaling in the medial prefrontal cortex plays a role in depression-like phenotype","volume":"7","author":"Zhang","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2023.115876_bib16","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13195-019-0554-4","article-title":"EphA4 loss improves social memory performance and alters dendritic spine morphology without changes in amyloid pathology in a mouse model of Alzheimer's disease","volume":"11","author":"Poppe","year":"2019","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.ejmech.2023.115876_bib17","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1172\/JCI131493","article-title":"EphA4\/Tie2 crosstalk regulates leptomeningeal collateral remodeling following ischemic stroke","volume":"130","author":"Okyere","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejmech.2023.115876_bib18","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1038\/s41467-021-23075-2","article-title":"Human ribonuclease 1 serves as a secretory ligand of ephrin A4 receptor and induces breast tumor initiation","volume":"12","author":"Lee","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115876_bib19","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.156319","article-title":"Monocyte proinflammatory phenotypic control by ephrin type A receptor 4 mediates neural tissue damage","volume":"7","author":"Kowalski","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.ejmech.2023.115876_bib20","doi-asserted-by":"crossref","DOI":"10.1172\/JCI161559","article-title":"The Eph receptor A4 plays a role in demyelination and depression-related behavior","volume":"132","author":"Li","year":"2022","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejmech.2023.115876_bib21","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/jbmr.4500","article-title":"A novel EphA4 signaling-based therapeutic strategy for osteoarthritis in mice","volume":"37","author":"Stiffel","year":"2022","journal-title":"J. Bone Miner. Res. : the official journal of the American Society for Bone and Mineral Research"},{"key":"10.1016\/j.ejmech.2023.115876_bib22","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13748","article-title":"Exosomal miR-532-5p induced by long-term exercise rescues blood-brain barrier function in 5XFAD mice via downregulation of EPHA4","volume":"22","author":"Liang","year":"2023","journal-title":"Aging Cell"},{"key":"10.1016\/j.ejmech.2023.115876_bib23","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1038\/s41467-022-31124-7","article-title":"EphB4 and ephrinB2 act in opposition in the head and neck tumor microenvironment","volume":"13","author":"Bhatia","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115876_bib24","doi-asserted-by":"crossref","first-page":"5532","DOI":"10.1111\/ejn.15591","article-title":"Mechanistic and therapeutic implications of EphA-4 receptor tyrosine kinase in the pathogenesis of Alzheimer's disease","volume":"56","author":"Ganguly","year":"2022","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.ejmech.2023.115876_bib25","series-title":"Unraveling the Potential of EphA4: A Breakthrough Target and Beacon of Hope for Neurological Diseases","author":"Verma","year":"2023"},{"key":"10.1016\/j.ejmech.2023.115876_bib26","doi-asserted-by":"crossref","first-page":"102","DOI":"10.4161\/cam.19620","article-title":"Profiling Eph receptor expression in cells and tissues: a targeted mass spectrometry approach","volume":"6","author":"Noberini","year":"2012","journal-title":"Cell Adhes. Migrat."},{"key":"10.1016\/j.ejmech.2023.115876_bib27","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/nrm1662","article-title":"Eph receptor signalling casts a wide net on cell behaviour","volume":"6","author":"Pasquale","year":"2005","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2023.115876_bib28","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1083\/jcb.200610139","article-title":"The EphA4 receptor regulates dendritic spine remodeling by affecting beta1-integrin signaling pathways","volume":"178","author":"Bourgin","year":"2007","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ejmech.2023.115876_bib29","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nn1811","article-title":"Cdk5 regulates EphA4-mediated dendritic spine retraction through an ephexin1-dependent mechanism","volume":"10","author":"Fu","year":"2007","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ejmech.2023.115876_bib30","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s12035-013-8580-x","article-title":"Ligand-dependent activation of EphA4 signaling regulates the proteolysis of amyloid precursor protein through a Lyn-mediated pathway","volume":"49","author":"Lai","year":"2014","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.ejmech.2023.115876_bib31","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1007\/s10753-018-0914-4","article-title":"Neuronal EphA4 regulates OGD\/R-Induced apoptosis by promoting alternative activation of microglia","volume":"42","author":"Wei","year":"2019","journal-title":"Inflammation"},{"key":"10.1016\/j.ejmech.2023.115876_bib32","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1002\/glia.24232","article-title":"EphA4 regulates white matter remyelination after ischemic stroke through Ephexin-1\/RhoA\/ROCK signaling pathway","volume":"70","author":"Liu","year":"2022","journal-title":"Glia"},{"key":"10.1016\/j.ejmech.2023.115876_bib33","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.neuron.2005.01.030","article-title":"Eph-dependent tyrosine phosphorylation of ephexin1 modulates growth cone collapse","volume":"46","author":"Sahin","year":"2005","journal-title":"Neuron"},{"key":"10.1016\/j.ejmech.2023.115876_bib34","doi-asserted-by":"crossref","first-page":"16347","DOI":"10.1073\/pnas.0706626104","article-title":"Alpha2-chimaerin interacts with EphA4 and regulates EphA4-dependent growth cone collapse","volume":"104","author":"Shi","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2023.115876_bib35","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1089\/neu.2012.2729","article-title":"Acute delivery of EphA4-Fc improves functional recovery after contusive spinal cord injury in rats","volume":"30","author":"Spanevello","year":"2013","journal-title":"J. Neurotrauma"},{"key":"10.1016\/j.ejmech.2023.115876_bib36","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1111\/j.1460-9568.2006.04704.x","article-title":"Accumulation of the inhibitory receptor EphA4 may prevent regeneration of corticospinal tract axons following lesion","volume":"23","author":"Fabes","year":"2006","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.ejmech.2023.115876_bib37","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1021\/acsmedchemlett.6b00132","article-title":"Modifications of a nanomolar cyclic peptide antagonist for the EphA4 receptor to achieve high plasma stability","volume":"7","author":"Olson","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115876_bib38","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.3389\/fnins.2019.01191","article-title":"EphA4 negatively regulates myelination by inhibiting schwann cell differentiation in the peripheral nervous system","volume":"13","author":"Chen","year":"2019","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.ejmech.2023.115876_bib39","doi-asserted-by":"crossref","first-page":"12524","DOI":"10.1073\/pnas.0903328106","article-title":"Glial ephrin-A3 regulates hippocampal dendritic spine morphology and glutamate transport","volume":"106","author":"Carmona","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2023.115876_bib40","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3389\/fnins.2015.00469","article-title":"Chronic glutamate toxicity in neurodegenerative diseases-what is the evidence?","volume":"9","author":"Lewerenz","year":"2015","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.ejmech.2023.115876_bib41","article-title":"Is L-glutamate toxic to neurons and thereby contributes to neuronal loss and neurodegeneration?","volume":"12","author":"Al-Nasser","year":"2022","journal-title":"A Systematic Review, Brain Sci"},{"key":"10.1016\/j.ejmech.2023.115876_bib42","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.mcn.2003.08.006","article-title":"Targeting the EphA4 receptor in the nervous system with biologically active peptides","volume":"24","author":"Murai","year":"2003","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.ejmech.2023.115876_bib43","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/j.1747-0285.2011.01199.x","article-title":"A disalicylic acid-furanyl derivative inhibits ephrin binding to a subset of Eph receptors","volume":"78","author":"Noberini","year":"2011","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2023.115876_bib44","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.2174\/1389450116666150727115934","article-title":"Targeting the Eph system with peptides and peptide conjugates","volume":"16","author":"Riedl","year":"2015","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.ejmech.2023.115876_bib45","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/hmg\/ddz288","article-title":"Environmental enrichment during the chronic phase after experimental stroke promotes functional recovery without synergistic effects of EphA4 targeted therapy","volume":"29","author":"de Boer","year":"2020","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ejmech.2023.115876_bib46","doi-asserted-by":"crossref","first-page":"11452","DOI":"10.1074\/jbc.M116.774141","article-title":"Identification and characterization of Nanobodies targeting the EphA4 receptor","volume":"292","author":"Schoonaert","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115876_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0042120","article-title":"A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo","volume":"7","author":"Petty","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2023.115876_bib48","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ejmech.2017.07.029","article-title":"Targeting Eph\/ephrin system in cancer therapy","volume":"142","author":"Lodola","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115876_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.104877","article-title":"EphA4 targeting agents protect motor neurons from cell death induced by amyotrophic lateral sclerosis -astrocytes","volume":"25","author":"Dennys","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.ejmech.2023.115876_bib50","doi-asserted-by":"crossref","DOI":"10.3390\/ph15020137","article-title":"Protein-protein interaction inhibitors targeting the eph-ephrin system with a focus on amino acid conjugates of bile acids","volume":"15","author":"Guidetti","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2023.115876_bib51","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nbt1358","article-title":"A quantitative analysis of kinase inhibitor selectivity","volume":"26","author":"Karaman","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejmech.2023.115876_bib52","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.semcdb.2011.10.023","article-title":"Targeting Eph receptors with peptides and small molecules: progress and challenges","volume":"23","author":"Noberini","year":"2012","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.ejmech.2023.115876_bib53","doi-asserted-by":"crossref","first-page":"6519","DOI":"10.1038\/s41598-017-06685-z","article-title":"Glycoengineering of EphA4 Fc leads to a unique, long-acting and broad spectrum, Eph receptor therapeutic antagonist","volume":"7","author":"Pegg","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2023.115876_bib54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0255753","article-title":"Conjugates for use in peptide therapeutics: a systematic review and meta-analysis","volume":"17","author":"Wijesinghe","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2023.115876_bib55","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41573-022-00529-w","article-title":"Derivatization with fatty acids in peptide and protein drug discovery","volume":"22","author":"Kurtzhals","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.115876_bib56","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2165\/00003088-200140070-00005","article-title":"Pegylation: a novel process for modifying pharmacokinetics","volume":"40","author":"Harris","year":"2001","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2023.115876_bib57","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S1359-6446(05)03575-0","article-title":"PEGylation, successful approach to drug delivery","volume":"10","author":"Veronese","year":"2005","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2023.115876_bib58","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jconrel.2014.06.046","article-title":"Peg - a versatile conjugating ligand for drugs and drug delivery systems","volume":"192","author":"Kolate","year":"2014","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.ejmech.2023.115876_bib59","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.drudis.2014.10.003","article-title":"Peptide therapeutics: current status and future directions","volume":"20","author":"Fosgerau","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2023.115876_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2018.12.032","article-title":"A review of lipidation in the development of advanced protein and peptide therapeutics","volume":"295","author":"Menacho-Melgar","year":"2019","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.ejmech.2023.115876_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2021.108785","article-title":"From discovery to approval: a brief history of the compstatin family of complement C3 inhibitors","volume":"235","author":"Mastellos","year":"2022","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.ejmech.2023.115876_bib62","doi-asserted-by":"crossref","first-page":"25831","DOI":"10.3390\/ijms161025831","article-title":"Site-specific PEGylation of therapeutic proteins","volume":"16","author":"Dozier","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2023.115876_bib63","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1039\/c1py00034a","article-title":"FDA-approved poly(ethylene glycol)\u2013protein conjugate drugs","volume":"2","author":"Alconcel","year":"2011","journal-title":"Polym. Chem."},{"key":"10.1016\/j.ejmech.2023.115876_bib64","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nrd1576","article-title":"Cyclodextrin-based pharmaceutics: past, present and future","volume":"3","author":"Davis","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.115876_bib65","doi-asserted-by":"crossref","first-page":"35035","DOI":"10.1074\/jbc.M205854200","article-title":"Albumin binding as a general strategy for improving the pharmacokinetics of proteins","volume":"277","author":"Dennis","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115876_bib66","doi-asserted-by":"crossref","first-page":"10187","DOI":"10.1021\/jm301276e","article-title":"Bicyclization and tethering to albumin yields long-acting peptide antagonists","volume":"55","author":"Angelini","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115876_bib67","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028611","article-title":"PEGylation potentiates the effectiveness of an antagonistic peptide that targets the EphB4 receptor with nanomolar affinity","volume":"6","author":"Noberini","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2023.115876_bib68","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1021\/bc400380f","article-title":"Enhanced catalysis of oxime-based bioconjugations by substituted anilines","volume":"25","author":"Wendeler","year":"2014","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.ejmech.2023.115876_bib69","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ejmech.2015.01.014","article-title":"Peptide therapeutics: targeting the undruggable space","volume":"94","author":"Tsomaia","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115876_bib70","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nrd.2018.125","article-title":"Constrained peptides' time to shine?","volume":"17","author":"Morrison","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.115876_bib71","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41573-020-00135-8","article-title":"Trends in peptide drug discovery","volume":"20","author":"Muttenthaler","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.115876_bib72","doi-asserted-by":"crossref","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide","volume":"58","author":"Lau","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115876_bib73","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1001\/jama.2023.2438","article-title":"As ozempic's popularity soars, here's what to know about semaglutide and weight loss","volume":"329","author":"Suran","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.ejmech.2023.115876_bib74","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1042\/BJ20120408","article-title":"Distinctive binding of three antagonistic peptides to the ephrin-binding pocket of the EphA4 receptor","volume":"445","author":"Lamberto","year":"2012","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2023.115876_bib75","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cbpa.2017.02.006","article-title":"Cyclic peptide therapeutics: past, present and future","volume":"38","author":"Zorzi","year":"2017","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.115876_bib76","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1039\/D1CB00154J","article-title":"Cyclic peptide drugs approved in the last two decades (2001-2021)","volume":"3","author":"Zhang","year":"2022","journal-title":"RSC Chem Biol"},{"key":"10.1016\/j.ejmech.2023.115876_bib77","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1158\/1535-7163.MCT-19-1092","article-title":"MMAE delivery using the bicycle toxin conjugate BT5528","volume":"19","author":"Bennett","year":"2020","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2023.115876_bib78","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2174\/187231207780363606","article-title":"Application of simple mathematical expressions to relate half-lives of drugs in mice to those in humans","volume":"1","author":"Bachmann","year":"2007","journal-title":"Drug Metabol. Lett."},{"key":"10.1016\/j.ejmech.2023.115876_bib79","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/bdd.708","article-title":"Prediction of human clearance of therapeutic proteins: simple allometric scaling method revisited","volume":"31","author":"Wang","year":"2010","journal-title":"Biopharm Drug Dispos."},{"key":"10.1016\/j.ejmech.2023.115876_bib80","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fphar.2013.00155","article-title":"Lipid- and sugar-modified endomorphins: novel targets for the treatment of neuropathic pain","volume":"4","author":"Varamini","year":"2013","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115876_bib81","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1021\/mp400680d","article-title":"Strategies to deliver peptide drugs to the brain","volume":"11","author":"Lalatsa","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2023.115876_bib82","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrneurol.2017.188","article-title":"Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders","volume":"14","author":"Sweeney","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ejmech.2023.115876_bib83","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1107\/S0907444910007493","article-title":"Features and development of Coot","volume":"66","author":"Emsley","year":"2010","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1016\/j.ejmech.2023.115876_bib84","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1107\/S0907444911001314","article-title":"REFMAC5 for the refinement of macromolecular crystal structures","volume":"67","author":"Murshudov","year":"2011","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1016\/j.ejmech.2023.115876_bib85","doi-asserted-by":"crossref","first-page":"W249","DOI":"10.1093\/nar\/gkr431","article-title":"Rosetta FlexPepDock web server--high resolution modeling of peptide-protein interactions","volume":"39","author":"London","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2023.115876_bib86","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1124\/dmd.110.034066","article-title":"Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase","volume":"38","author":"Malm-Erjefalt","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejmech.2023.115876_bib87","doi-asserted-by":"crossref","first-page":"6126","DOI":"10.1021\/jm070861j","article-title":"Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness","volume":"50","author":"Madsen","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115876_bib88","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1006\/dbio.2000.0109","article-title":"Ephrin-A6, a new ligand for EphA receptors in the developing visual system","volume":"230","author":"Menzel","year":"2001","journal-title":"Dev. Biol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423008437?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423008437?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:58:36Z","timestamp":1759330716000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423008437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":88,"alternative-id":["S0223523423008437"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115876","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipidation and PEGylation strategies to prolong the in vivo half-life of a nanomolar EphA4 receptor antagonist","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115876","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115876"}}